Lower riskDrug recall · FDA · Published October 3, 2018
InvaGen Amlodipine Tablets Recall: Subpotent Drug Risk
InvaGen Pharmaceuticals recalls 10 mg Amlodipine Besylate tablets due to subpotent drug quality. This means the medication may not be as effective as labeled, potentially requiring higher doses for treatment.
Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long term stability condition.
Take action
Contact the company
📍Recalling firmInvaGen Pharmaceuticals, Inc.7 Oser Ave · Hauppauge, NY 11788-3811
✎ GovInfoNow plain-language explainer
InvaGen Pharmaceuticals is recalling 10 mg Amlodipine Besylate tablets that may not contain the full amount of active ingredient. This could lead to the medication being less effective than intended, requiring higher doses for the same treatment effect. Read more at govinfonow.com/recall/39538-invagen-amlodipine-tablets-recall-subpotent-drug-risk.
“InvaGen Amlodipine Tablets Recall: Subpotent Drug Risk.” GovInfoNow, updated October 6, 2026. https://govinfonow.com/recall/39538-invagen-amlodipine-tablets-recall-subpotent-drug-risk. Based on FDA recall #D-0012-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0012-2019%22&limit=1).
InvaGen Pharmaceuticals, Inc. voluntarily recalled Amlodipine Besylate USP 10 mg Tablets on Oct. 3, 2018, after the FDA announced one lot was subpotent. The Food and Drug Administration issued recall number D-0012-2019 for the Class III product distributed nationwide.
The FDA stated that one lot of the product does not meet the specification for the Assay test under 3-month long-term stability conditions, resulting in a subpotent drug. The record provides no information regarding incidents or injuries.
Context
GovInfoNow's records show InvaGen Pharmaceuticals, Inc. has had seven other recalls since March 5, 2018. Other recent recalls of similar products include Ascend Laboratories recalls Amlodipine/Olmesartan tablets with low drug content (July 8, 2026), Unichem busPIRone 5mg Tablets Recall: Subpotent Drug Risk (April 13, 2026), and Ascend Laboratories recalls 5mg/40mg blood pressure tablets due to low drug content (May 5, 2026).
How to tell if you have this one
Check for the lot number GG80218 on the bottle label. The product is a 1000-count bottle of 10 mg Amlodipine Besylate tablets, manufactured by Cipla Ltd. in India, with an expiration date of December 2019.
The recall indicates a potential issue with the medication's effectiveness, but it is not unsafe in terms of causing injury. The product may require higher doses for the same effect.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0012-2019 (October 3, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0012-2019 to see it in context.
Plain-language summary written by qwen3:4b on October 6, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.